EHDN plenary meetings

virtual bridging EHDN banner

When: September 11, 2020 Time: 14:00 — 18:15 CET

View the programme

Recorded sessions:
Welcome and introduction

Anne Rosser
Astri Arnesen
Patrick Weydt

Scientific progress session

  • Chair: Lesley Jones
  • Function of HTT — Frédéric Saudou
  • Somatic expansion of the HTT CAG repeat — Darren Monckton
  • HTT phosphorylation and TBK1 — Hilal Lashuel
  • Oral HTT-lowering therapy — George McAllister
  • Q&A and Discussion
Clinical studies session — PART 1

  • Chair: Jean-Marc Burgunder
  • An Update from the Tominersen Global Clinical Development Programme — Sarah Tabrizi
  • PRECISION HD1 and 2: allele selective targeting of the mutant HTT — Anna Heinzmann
  • Shield-HD — Anne Rosser
  • Prilenia — Bernhard Landwehrmeyer
  • First Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest HD — Ralf Reilmann
Clinical studies session — PART 2

  • Chair: Jean-Marc Burgunder
  • MIG-HD trial — Anne-Catherine Bachoud-Levi
  • HEATED- Huntington’s Equal Access to Effective Drugs — Hugh Rickards
  • Q&A and Discussion
Closing remarks

Bernhard Landwehrmeyer
Anne Rosser

Plenary Meeting EHDN2021

Logo-bologna-2021-final-255x85px

Every second year in September EHDN hosts one of the world’s largest conferences dedicated solely to Huntington’s disease. The 2021 EHDN plenary meeting takes place September 10th — 12th in the Bologna Congress Center and is organised in conjunction with the European Huntington Association (EHA) meeting. The scientific programme includes recent advances in both basic and clinical HD research and attendees have the opportunity to meet experts in the field of HD studies in more informal settings. All EHDN plenary sessions are open to clinicians, scientists, EHA delegates and members of families affected by HD. For more information about this year’s meeting please read here.